Gain Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Dov A Goldstein, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.
NASDAQ
Claude Nicaise, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.
NASDAQ
Khalid Islam, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.
NASDAQ
Gwen A Melincoff, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.
NASDAQ
Jeffrey Scott Riley, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.
NASDAQ
Hans Peter Hasler, a Director of Gain Therapeutics, Inc., received 25,000 shares of common stock on July 15, 2026.
NASDAQ
Gain Therapeutics' CEO and President, Gene Mack, was granted 200,000 employee stock options with an exercise price of $1.86.
NASDAQ
Gain Therapeutics' Principal Accounting and Financial Officer, Gianluca Fuggetta, was granted 50,000 employee stock options with an exercise price of $1.86.
NASDAQ
Gain Therapeutics, Inc. Director Khalid Islam was granted 15,000 stock options with an exercise price of $1.79, vesting over 12 months.
NASDAQ
Gain Therapeutics, Inc. Director Claude Nicaise was granted 15,000 stock options with an exercise price of $1.79, vesting over 12 months.
NASDAQ
Jeffrey Scott Riley, a Director at Gain Therapeutics, Inc., was granted 15,000 stock options with an exercise price of $1.79 per share, vesting over 12 months.
NASDAQ
Gain Therapeutics, Inc. Director Eric I. Richman was granted 15,000 stock options with an exercise price of $1.79, vesting monthly over one year starting July 24, 2025.
NASDAQ
Gain Therapeutics, Inc. Director Hans Peter Hasler was granted 15,000 stock options with an exercise price of $1.79, vesting over 12 months.
NASDAQ
Dov A. Goldstein, a Director and 10% Owner of Gain Therapeutics, Inc., acquired 15,000 stock options with an exercise price of $1.79, vesting over 12 months.
NASDAQ
Gain Therapeutics, Inc. Director Gwen A. Melincoff was granted 15,000 stock options with an exercise price of $1.79, vesting over 12 months.
NASDAQ
Gianluca Fuggetta, Principal Accounting and Financial Officer of Gain Therapeutics, Inc., acquired options to purchase 50,000 shares of common stock on March 20, 2025.
NASDAQ
Gene Mack, CEO and President of Gain Therapeutics, Inc., reports the acquisition of 200,000 employee stock options.
NASDAQ
Gain Therapeutics CEO, Gene Mack, acquired 271,325 stock options on January 6, 2025, which vest over a period of four years.
NASDAQ
Gene Mack, CFO and Interim CEO of Gain Therapeutics, Inc., purchased 14,400 shares of common stock at an average price of $1.01 on August 9, 2024.
NASDAQ
Khalid Islam, Executive Chairman of Gain Therapeutics, Inc., purchased 50,000 shares of common stock at an average price of $0.9988 on August 9, 2024.
NASDAQ
Director Eric Richman reports purchasing additional shares of Gain Therapeutics, Inc. common stock.
NASDAQ
Director Khalid Islam acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
NASDAQ
Director Gwen A. Melincoff acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
NASDAQ
Director Hans Peter Hasler acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
NASDAQ
Director Claude Nicaise acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
NASDAQ
Eric I. Richman, a director of Gain Therapeutics, Inc., acquired 15,000 stock options on June 24, 2024, at an exercise price of $1.29.
NASDAQ
Director Dov A. Goldstein acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
NASDAQ
Director Jeffrey Scott Riley acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
NASDAQ
Gene Mack, CFO of Gain Therapeutics, Inc., was granted 200,000 employee stock options on April 8, 2024, vesting over four years.
NASDAQ
Director Jeffrey Scott Riley purchased 30,000 shares of Gain Therapeutics, Inc. common stock at an average price of $3.859 on March 28, 2024.